Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

ROS-independent Nrf2 activation in prostate cancer.

Publication ,  Journal Article
Bellezza, I; Scarpelli, P; Pizzo, SV; Grottelli, S; Costanzi, E; Minelli, A
Published in: Oncotarget
September 2017

In prostate cancer, oxidative stress and the subsequent Nrf2 activation promote the survival of cancer cells and acquired chemoresistance. Nrf2 links prostate cancer to endoplasmic reticulum stress, an event that triggers the unfolded protein response, aiming to restore cellular homeostasis as well as an adaptive survival mechanism. Glucose-regulated protein of 78 kD /immunoglobulin heavy chain binding protein (GRP78/BiP) is a key molecular chaperone in the endoplasmic reticulum that, when expressed at the cell surface, acts as a receptor for several signaling pathways enhancing antiapoptotic and proliferative signals. We showed GRP78/BiP translocation to PC3 cell surface in the presence of tunicamycin, an ER stress inductor, and demonstrated the existence of a GRP78/BiP-dependent non-canonical Nrf2 activation, responsible for increased resistance to ER-stress induced apoptosis. We found that, even in the absence of ROS production, tunicamycin causes Nrf2 activation, and activates Akt signaling, events bulnted by anti-GRP78/BiP antibody treatment. The presence of GRP78/BiP at the cell surface might be exploited for the immunotherapeutic strategy of prostate cancer since its blockage by anti-GRP78/BiP antibodies might promote cancer death by suppressing some of the several molecular protective mechanisms found in aggressive cancer cells.

Duke Scholars

Published In

Oncotarget

DOI

EISSN

1949-2553

ISSN

1949-2553

Publication Date

September 2017

Volume

8

Issue

40

Start / End Page

67506 / 67518

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bellezza, I., Scarpelli, P., Pizzo, S. V., Grottelli, S., Costanzi, E., & Minelli, A. (2017). ROS-independent Nrf2 activation in prostate cancer. Oncotarget, 8(40), 67506–67518. https://doi.org/10.18632/oncotarget.18724
Bellezza, Ilaria, Paolo Scarpelli, Salvatore V. Pizzo, Silvia Grottelli, Egidia Costanzi, and Alba Minelli. “ROS-independent Nrf2 activation in prostate cancer.Oncotarget 8, no. 40 (September 2017): 67506–18. https://doi.org/10.18632/oncotarget.18724.
Bellezza I, Scarpelli P, Pizzo SV, Grottelli S, Costanzi E, Minelli A. ROS-independent Nrf2 activation in prostate cancer. Oncotarget. 2017 Sep;8(40):67506–18.
Bellezza, Ilaria, et al. “ROS-independent Nrf2 activation in prostate cancer.Oncotarget, vol. 8, no. 40, Sept. 2017, pp. 67506–18. Epmc, doi:10.18632/oncotarget.18724.
Bellezza I, Scarpelli P, Pizzo SV, Grottelli S, Costanzi E, Minelli A. ROS-independent Nrf2 activation in prostate cancer. Oncotarget. 2017 Sep;8(40):67506–67518.

Published In

Oncotarget

DOI

EISSN

1949-2553

ISSN

1949-2553

Publication Date

September 2017

Volume

8

Issue

40

Start / End Page

67506 / 67518

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis